A Phase 1, Open-Label, Randomized, Single Dose Study To Estimate The Relative Bioavailability And Food Effect Of PF‑06291826 (Tafamidis) Following Administration Of New Soft Gelatin Capsule Oral Formulations In Healthy Subjects

Trial Profile

A Phase 1, Open-Label, Randomized, Single Dose Study To Estimate The Relative Bioavailability And Food Effect Of PF‑06291826 (Tafamidis) Following Administration Of New Soft Gelatin Capsule Oral Formulations In Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2015

At a glance

  • Drugs Tafamidis meglumine (Primary)
  • Indications Amyloid polyneuropathy; Cardiomyopathies
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Dec 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 05 Oct 2015 Planned number of patients changed from 30 to 18 as reported by ClinicalTrials.gov.
    • 05 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top